LSD1-IN-24
Modify Date: 2024-02-01 10:28:10
LSD1-IN-24 structure
|
Common Name | LSD1-IN-24 | ||
|---|---|---|---|---|
| CAS Number | 4734-59-2 | Molecular Weight | 312.43 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H20N2OS | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LSD1-IN-24LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC50 = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research[1]. |
| Name | LSD1-IN-24 |
|---|
| Description | LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC50 = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | LSD1-IN-24 (compound 3S)(0-20 μM, 5 days) 可以以 LSD1 依赖性方式降低 PD-L1 水平并以剂量依赖性方式增强 BGC-823 细胞的 T 细胞杀伤反应，但不影响 BGC-823 和 MFC 细胞增殖。此外，它可以剂量依赖性地保护 H3K4me1/2 免于去甲基化，但不能保护 H3K4me3[1]。 |
| In Vivo | LSD1-IN-24 (compound 3S) (0-50 mg/kg, oral gavage; daily for 2 weeks) 在含 MFC 细胞的皮下肿瘤模型中，以剂量依赖的方式抑制体内 MFC 细胞的生长，肿瘤的重量明显下降，肿瘤组织 Ki67 明显降低，并且对小鼠无明显毒性作用[1]。 Animal Model: Male 615 mice with MFC cell[1] Dosage: 0, 10, 25, and 50 mg/kg Administration: Oral gavage; daily for 2 weeks Result: Significantly decreased intratumoral PD-L1 expression, increased CD3+, CD4+, CD8+ cell numbers, interleukin-2 (IL2) and IFNγ mRNA and protein levels were also upregulated. |
| References |
| Molecular Formula | C18H20N2OS |
|---|---|
| Molecular Weight | 312.43 |